Cancer Research and Cellular Therapeutics,
Journal Year:
2023,
Volume and Issue:
8(2), P. 01 - 06
Published: March 20, 2023
Background:
Colorectal
cancer
(CRC)
is
a
leading
cause
of
deaths
worldwide.
Key
risk
factors
include
lifestyle,
diet,
inflammation,
and
family
history.
Understanding
molecular
pathways
underlying
CRC
initiation
progression
critical
to
guide
prevention
treatment.
Purpose:
This
review
summarizes
recent
advances
in
screening,
therapy,
future
directions.
Main
body:
New
stool
DNA
panels
blood-based
assays
offer
non-invasive
options
for
early
detection,
though
require
further
validation.
Immuno-
targeted
therapies
matched
tumor
profiles
have
transformed
metastatic
Pembrolizumab
elicits
durable
responses
mismatch
repair-deficient
tumors,
anti-EGFR
antibodies
cetuximab/panitumumab
improve
outcomes
left-sided
RAS/RAF
wild-type
CRC.
Larotrectinib
entrectinib
are
highly
active
NTRK
fusion-positive
Research
focusing
on
new
immunotherapies,
leveraging
the
microbiome,
combining
multi-omics
data
enable
precision
medicine
holds
promise.
Disparities
across
groups
remain
challenge.
Conclusions:
Recent
therapeutic
significantly
improved
survival
patients.
Advances
diagnostics,
next-generation
sequencing,
computational
approaches
will
more
sophisticated
profiling
tailored
therapy
selection.
Realizing
potential
emerging
immunotherapies
integrating
knowledge
microbiome
important
frontiers.
Discover Oncology,
Journal Year:
2024,
Volume and Issue:
15(1)
Published: June 12, 2024
Colorectal
cancer,
which
originates
from
the
human
colon
or
rectum,
is
one
of
leading
causes
death
worldwide.
Timely
diagnosis
and
interventional
therapy
can
significantly
improve
prognostic
survival
colorectal
cancer
patients,
making
regular
screening
early
detection
essential.
Nanomaterials,
Journal Year:
2024,
Volume and Issue:
14(20), P. 1657 - 1657
Published: Oct. 16, 2024
The
combination
of
paclitaxel
(PTX)
with
other
chemotherapy
drugs
(e.g.,
gemcitabine,
GEM)
or
genetic
siRNA)
has
been
shown
to
enhance
therapeutic
efficacy
against
tumors,
reduce
individual
drug
dosages,
and
prevent
resistance
associated
single-drug
treatments.
However,
the
varying
solubility
presents
a
challenge
in
co-delivering
these
agents.
In
this
study,
nanoparticles
loaded
PTX
were
prepared
using
biodegradable
polymer
material
poly(3-hydroxybutyrate-co-3-hydroxyhexanoate)
(PHBHHx).
These
surface-modified
target
proteins
(Affibody
molecules)
RALA
cationic
peptides
create
core-shell
structured
microspheres
targeted
functionalization.
A
three-drug
co-delivery
system
(PTX@PHBHHx-ARP/siRNA
Cancer Research and Cellular Therapeutics,
Journal Year:
2023,
Volume and Issue:
8(2), P. 01 - 06
Published: March 20, 2023
Background:
Colorectal
cancer
(CRC)
is
a
leading
cause
of
deaths
worldwide.
Key
risk
factors
include
lifestyle,
diet,
inflammation,
and
family
history.
Understanding
molecular
pathways
underlying
CRC
initiation
progression
critical
to
guide
prevention
treatment.
Purpose:
This
review
summarizes
recent
advances
in
screening,
therapy,
future
directions.
Main
body:
New
stool
DNA
panels
blood-based
assays
offer
non-invasive
options
for
early
detection,
though
require
further
validation.
Immuno-
targeted
therapies
matched
tumor
profiles
have
transformed
metastatic
Pembrolizumab
elicits
durable
responses
mismatch
repair-deficient
tumors,
anti-EGFR
antibodies
cetuximab/panitumumab
improve
outcomes
left-sided
RAS/RAF
wild-type
CRC.
Larotrectinib
entrectinib
are
highly
active
NTRK
fusion-positive
Research
focusing
on
new
immunotherapies,
leveraging
the
microbiome,
combining
multi-omics
data
enable
precision
medicine
holds
promise.
Disparities
across
groups
remain
challenge.
Conclusions:
Recent
therapeutic
significantly
improved
survival
patients.
Advances
diagnostics,
next-generation
sequencing,
computational
approaches
will
more
sophisticated
profiling
tailored
therapy
selection.
Realizing
potential
emerging
immunotherapies
integrating
knowledge
microbiome
important
frontiers.
